Secor Capital Advisors’s Akebia Therapeutics AKBA Stock Holding History

Secor Capital Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-62,495	Closed	-$346K	–	397
2018 Q4	$346K	Buy	62,495 +30,606	+96%	+$240K	0.05%	353
2018 Q3	$282K	Sell	31,889 -144,330	-82%	-$1.29M	0.03%	374
2018 Q2	$1.76M	Buy	176,219 +106,470	+153%	+$1.07M	0.15%	210
2018 Q1	$665K	Buy	69,749 +21,314	+44%	+$298K	0.05%	348
2017 Q4	$720K	Buy	+48,435	New	+$803K	0.03%	322
2017 Q2	–	Sell	-32,233	Closed	-$297K	–	447
2017 Q1	$297K	Sell	32,233 -2,256	-7%	-$22K	0.03%	405
2016 Q4	$359K	Buy	+34,489	New	+$297K	0.04%	388

Other funds holding AKBA

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Secor Capital Advisors's AKBA Position: Q1 2019 in Review

Secor Capital Advisors sold out of Akebia Therapeutics (AKBA) in Q1 2019, closing a stake of 62,495 shares — an estimated $346K sold.

Secor Capital Advisors first reported a position in AKBA in Q4 2016 and held it in 7 quarters. The position peaked at $1.76M in Q2 2018. 169 funds tracked by Wall St. Rank hold AKBA as of Q1 2019.

Secor Capital Advisors reported no remaining Akebia Therapeutics position as of Q1 2019 after selling out during the quarter.
Secor Capital Advisors sold 62,495 Akebia Therapeutics shares in Q1 2019, an estimated $346K.
Secor Capital Advisors first reported a position in Akebia Therapeutics in Q4 2016 and held it in 7 quarters.
Secor Capital Advisors's Akebia Therapeutics position peaked at $1.76M in Q2 2018.
169 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2019.

Based on Secor Capital Advisors's 13F filing for Q1 2019, filed 15 May 2019.